<DOC>
	<DOCNO>NCT00297648</DOCNO>
	<brief_summary>The aim study investigate effect certolizumab pegol intestinal mucosa active Crohn 's disease .</brief_summary>
	<brief_title>Mucosal Healing Study Crohn 's Disease ( CD )</brief_title>
	<detailed_description />
	<mesh_term>Crohn Disease</mesh_term>
	<mesh_term>Certolizumab Pegol</mesh_term>
	<criteria>Patients suffer active Crohn 's disease [ Crohn 's Disease Activity Index ( CDAI ) ≥ 220 ≤ 450 ] least 2 segment endoscopic ulcerative lesion Baseline Crohn 's Disease Endoscopic Index Severity ( CDEIS ) ≥ 8 Patients need treat antitumor necrosis factor ( antiTNF ) therapy Obstructive intestinal stricture , bowel resection , proctocolectomy total colectomy , current total parenteral nutrition , short bowel syndrome History tuberculosis positive test tuberculosis screen All concomitant diseases pathological condition could interfere Crohn 's disease assessment harmful well patient Previous clinical trial previous biological therapy could interfere result present clinical trial</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2011</verification_date>
	<keyword>Certolizumab pegol</keyword>
	<keyword>Crohn 's disease</keyword>
	<keyword>Mucosal heal</keyword>
</DOC>